logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Refuses To Approve Alexza's Adasuve On Manufacturing Issues, Shares Plunge

Alexza Pharmaceuticals, Inc. (ALXA) Thursday said it has received a Complete Response Letter or CRL from the U.S. Food and Drug Administration regarding its New Drug Application for Adasuve (loxapine) inhalation powder, 5 mg and 10 mg, citing manufacturing deficiencies at its Mountain View, California facility. The stock fell about 37 percent in the extended trade.

Adasuve is being developed for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The letter indicated that the NDA review cycle was complete and the application was not ready for approval in its present form.

The FDA said in the letter, "During a recent inspection of the Mountain View, CA manufacturing facility for this application, our field investigator conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be approved."

The company had received a CRL from the FDA previously in October 2010, citing breathing-related concerns associated with Adasuve.

Alexza said Thursday that it believes the deficiencies in the latest CRL concern medical devices and can be addressed readily. The company said there were no new clinical or safety issues identified and there were no other deficiencies outlined in the CRL issued by FDA's Center for Drug Evaluation and Research.

Regarding the Adasuve Risk Evaluation and Mitigation Strategy or REMS, the CRL said discussions could continue on the proposed REMS after submitting the response to the action letter.

The CRL also contained comments on Alexza's draft product labeling. The company believes that it has substantial agreement with the FDA on the REMS and product labeling.

Alexza plans to meet with the FDA as soon as practical to gain a better understanding of the specific deficiencies.

The firm said it looks forward to working to resolve the remaining issues in a timely manner.

ALXA closed on Thursday at $0.61, down $0.08 or 11.59 percent from the previous close, on 11.54 million shares compared to the 3-month average volume of 1.48 million shares. The stock declined $0.32 or 36.9 percent in the extended trade.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Consumers in Nigeria are calling for a boycott of Coca-Cola products sold in the African nation after a high court judge ruled that the products could be "poisonous". Justice Adedayo Oyebanji of the Lagos High Court ruled that high levels of benzoic acid and sunset additives in Coca-Cola's soft drinks could pose a health risk to consumers when mixed with ascorbic acid, commonly known as Vitamin C. Charles Murphy, a partner at New York hedge fund Paulson & Co., fell to his death after jumping out of a hotel window in Manhattan on Monday. Murphy was found dead on the fourth-floor terrace of the Sofitel New York Hotel after he jumped from a window on the 24th floor. Internet media company BuzzFeed is preparing to go public in 2018, media site Axios reported Wednesday, citing industry sources. New York-based BuzzFeed was founded in 2006 by Jonah Peretti and John Johnson III as a viral lab, focusing exclusively on tracking viral content.
comments powered by Disqus
Follow RTT